GlassScriptPhysician profile
Kelly Conner
NPI 1801039722
$6,953.01
in general payments reported to CMS, 2019-2025
29 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $418 · 2021: $829 · 2022: $1,058 · 2023: $1,700 · 2024: $1,235 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.63 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.30 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,052.18 | 2019-2025 | |
| Janssen Biotech, INC. | $744.17 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $629.32 | 2020-2024 | Dupixent |
| Genzyme Corporation | $427.13 | 2022-2025 | |
| Galderma Laboratories, L.P. | $415.55 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Amgen INC. | $349.65 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $236.76 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $234.19 | 2021-2024 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $213.18 | 2022-2024 | Sotyktu |
| Strata Skin Sciences, INC. | $165.69 | 2020-2025 | Xtrac |
| Mayne Pharma Commercial LLC | $162.20 | 2019-2023 | |
| Pfizer INC. | $134.31 | 2023-2025 | |
| Lilly USA, LLC | $114.04 | 2019-2024 | Taltz, Olumiant |
| Revance Therapeutics, INC. | $99.16 | 2024-2025 | Daxxify |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $77.15 | 2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $75.33 | 2020-2021 | |
| Journey Medical Corporation | $58.23 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $57.09 | 2023-2024 | Zoryve |
| Almirall LLC | $48.22 | 2019 | |
| Dermavant Sciences, INC. | $45.30 | 2023 | Vtama |
| Leo Pharma INC. | $40.00 | 2019-2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.67 | 2022-2023 | Spevigo |
| Botanix Sb INC | $32.17 | 2025 | Sofdra |
| Genentech USA, INC. | $26.34 | 2019 | |
| Organon LLC | $23.66 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.35 | 2023 | Arazlo, Jublia |
| Allergan, INC. | $18.19 | 2021 | |
| Celgene Corporation | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.